Miles Blanco already sending out in prep of next weeks sales, blaming exchange rates for the poor showing. So who was the rocket scientist to invest in all of the tanking emerging markets. Been in the job since 99. He has got to go. No stock split on his watch. Talking 17 years now. Only smoke and mirrors with mergers and acquisitions. The dividend is next 2 nothing. So what else you gonna outsource. Anything left, I know start with some of the VPs. Who is guiding this sinking ship.
Less than 200 views after a few days, guess there arent that many folks interested in angry statements with little substance about a great company. Name another company in Abbott's peer group that has had a stock split since 1999? Give an analysis, not a grumpy stump.
You can do better elsewhere. The dividend is almost worthless after taxes. Could do better with or stocks. Dump this laggard.
OK Blanco is now blaming exchange rates and Venezuela. Abbott sells lets say 20 Billion to keep it at a round #. Anyone know how much sales Venezuela brings in annually and how much of a loss would be expected in 2016. Sorry but Venezuela is not the issue. Only a diversion to the boards incompetence.
Anyone who can drive growth. The current p/e ratio is much too high. Miles has been in the job for 18 years. His claim to fame is a failed acquisition by GE for the diagnostics, regulatory problems with ADD, the spin-off of HPD , the purchase of a medical device suture company, and the splitting of the company in two. Is this worth the over 200 million plus we as stock holders have paid this guy? I think not !! Time for him to get out and go live on the 20 acres he purchased 16 years ago for the new Perclose building. Prime property and directly next to his Stanford rowing buddies.
I agree he needs to go. Maybe with our low evaluation we will be bought up and split up. Wow 26 cent dividend before taxes kick in. We can do way better with Abbvie that he jettisoned.
I agree he needs to go. Maybe with our low evaluation we will be bought up and split up. Wow 26 cent dividend before taxes kick in. We can do way better with Abbvie that he jettisoned.
Anyone who can drive growth. The current p/e ratio is much too high. Miles has been in the job for 18 years. His claim to fame is a failed acquisition by GE for the diagnostics, regulatory problems with ADD, the spin-off of HPD , the purchase of a medical device suture company, and the splitting of the company in two. Is this worth the over 200 million plus we as stock holders have paid this guy? I think not !! Time for him to get out and go live on the 20 acres he purchased 16 years ago for the new Perclose building. Prime property and directly next to his Stanford rowing buddies.
What Makes Abbott Laboratories (ABT) a Strong Sell? Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Abbott Laboratories ABT, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in ABT. A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 11 estimates moving down in the past 30 days, compared to no upward revision. This trend has caused the consensus estimate to trend lower, going from $2.39 per share a month ago to its current level of $2.15 per share. Also, for the current quarter, Abbott Laboratories has seen 4 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to 39 cents a share from 50 cents over the past 30 days. The stock also has seen some pretty dismal trading lately, as the share price has dropped 11.7% in the past month. So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait. If you are still interested in the Medical sector, you may instead consider a better-ranked stock - AstraZeneca PLC AZN. The stock currently holds a Zacks Rank #2 (Buy) and may be better selection at this time.
When Abbott sold the EPD DM business to Mylan. Abbott received shares in Mylan. Did Abbott sell off these Mylan shares or are we now stuck with them. Mylan down 19% today.
